Ayala Pharmaceuticals is a clinical-stage precision oncology company dedicated to developing and commercializing potential small molecule therapeutics for patients suffering from rare and aggressive cancers, especially in genetically defined patient populations. Ayalas product candidates, AL101 and AL102, are designed to target cancer by addressing the underlying key drivers of tumor growth. Both product candidates target the aberrant activation of the Notch pathway with gamma-secretase inhibitors (GSIs). By developing drugs designed to inhibit Notch pathway activation, Ayala is enabling personalized therapy for cancer patients. In 2017, the company entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for its gamma-secretase inhibitors. Ayalas lead product, AL101, granted orphan drug designation by the FDA in 2019, has completed preclinical and phase 1 studies. A phase 2 study (ACCURACY) for AL101 in patients with adenoid cystic carcinoma bearing activated Notch mutations has been initiated. In 2018, Ayala entered into a deal with Novartis to develop and commercialize AL102 in combination with BCMA-targeting agents in multiple myeloma. In addition, Ayala is evaluating AL102 as an inhibitor of the Notch pathway in hematologic cancers.